CCL2, a monocyte-specific surface marker that induces local inflammation and accelerates atherosclerosis, showed an upregulation on mRNA and protein levels for only 3R4F but not consistently for NGP treatment. This evidence concerns the gene CCL2 and atherosclerosis.